Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

A user shared a 7-month update on hair regrowth using finasteride daily and minoxidil once a day, noting improvement in hair health. Others suggested adding micro-needling, ketoconazole shampoo, and considering a hair transplant for better results.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation discusses the lack of clinical studies on cysteine alone for hair loss, with the original poster already using medications like Minoxidil and finasteride. Suggestions include trying 2ddr as a growth stimulant, though concerns about side effects like gas are mentioned.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.